In a systematic review by Kaplan et al., the 5-year survival rate for patients with PCM1-JAK2 fusion-associated ALL was reported to be 40.0% (6.6–73.4%) [18]. The gene discussed is PCM1; the disease is acute lymphoblastic leukemia.